webinar
ADCs (Antibody Drug Conjugates) combines the best of two modalities, toxic efficacy, and antibody specificity. The result is an improved therapeutic window with fewer side effects. However, the bioanalytical requirements for PK analysis also require a multifaceted approach. Here we describe various mass spectrometry-based strategies Frontage has successfully applied in the bioanalysis of ADCs for clinical and preclinical studies.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.